case report | Q2782326 |
scholarly article | Q13442814 |
P2093 | author name string | Parry A | |
Stacey R | |||
Baker I | |||
Wimalaratna S | |||
P2860 | cites work | Unsuccessful intraventricular pentosan polysulphate treatment of variant Creutzfeldt-Jakob disease | Q34511219 |
Treatment of transmissible spongiform encephalopathy by intraventricular drug infusion in animal models | Q37730189 | ||
Cerebroventricular infusion of pentosan polysulphate in human variant Creutzfeldt-Jakob disease. | Q46501596 | ||
P433 | issue | 7 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | patient | Q181600 |
Creutzfeldt-Jakob disease | Q49989 | ||
P304 | page(s) | 733-734 | |
P577 | publication date | 2007-02-21 | |
P1433 | published in | Journal of Neurology, Neurosurgery and Psychiatry | Q1599804 |
P1476 | title | Long term survival in a patient with variant Creutzfeldt-Jakob disease treated with intraventricular pentosan polysulphate | |
P478 | volume | 78 |
Q33957528 | Diphenylpyrazole-derived compounds increase survival time of mice after prion infection. |
Q33680310 | Glycosaminoglycan sulphation affects the seeded misfolding of a mutant prion protein |
Q33613234 | Heparin binding confers prion stability and impairs its aggregation |
Q39005891 | Insights from Therapeutic Studies for PrP Prion Disease |
Q40078261 | Orally administered amyloidophilic compound is effective in prolonging the incubation periods of animals cerebrally infected with prion diseases in a prion strain-dependent manner |
Q28551264 | Pentosan Polysulfate: Oral Versus Subcutaneous Injection in Mucopolysaccharidosis Type I Dogs |
Q33956775 | Postmortem findings in a case of variant Creutzfeldt-Jakob disease treated with intraventricular pentosan polysulfate |
Q26741258 | Prion diseases: immunotargets and therapy |
Q35832931 | Rapidly progressive dementias and the treatment of human prion diseases |
Q39236820 | Sulfated glycosaminoglycans in protein aggregation diseases |
Q36743340 | The variant Creutzfeldt-Jakob Disease: Risk, uncertainty or safety in the use of blood and blood derivatives? |
Q36901944 | Therapeutic approaches for prion disorders |
Q37199225 | Therapies for human prion diseases |
Q37080697 | Toxic effects of intracerebral PrP antibody administration during the course of BSE infection in mice |
Q34453109 | Variant CJD. 18 years of research and surveillance |
Search more.